Menu
Search
|

Menu

Close
X

Arsanis Inc ASNS.OQ (NASDAQ Stock Exchange Global Market)

2.86 USD
-0.17 (-5.61%)
As of 7:29 PM IST
chart
Previous Close 3.03
Open 3.01
Volume 7,139
3m Avg Volume 22,793
Today’s High 3.01
Today’s Low 2.85
52 Week High 27.83
52 Week Low 2.85
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.744
FY17
-2.884
FY16
-2.126
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Tillman Gerngross
Co-Founder, Chairman of the Board, Since
Salary: --
Bonus: --
Rene Russo
President, Chief Executive Officer, Director, Since 2015
Salary: --
Bonus: --
Eszter Nagy
Co-Founder, Chief Scientific Officer, Director, Since 2016
Salary: --
Bonus: --
Errik Anderson
Co-Founder, Since 2015
Salary: --
Bonus: --
Michael Gray
Chief Financial Officer, Chief Business Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

890 Winter St Ste 230
WALTHAM   MA   02451-1470

Phone: +1781.8195704

Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. Its lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. Its ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Its ASN400 addresses the unmet medical need due to streptococcus pneumoniae, a leading cause of mortality among the elderly. The ASN500 program consisting of potent mAbs targeting respiratory syncytial virus (RSV).

SPONSORED STORIES